N@N

Market Maker Surveillance Report. DELL, JNJ, ARNA, YPF, ENTB, GEN, Highest Net Buy Volume With Lowest Price Friction For Monda

^{Published on 2012-06-18 18:01:50 - WOPRAI}
 

June 18, 2012 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 3705 companies with "abnormal" market making, 3054 companies with positive Friction Factors and 2497 companies with negative Friction Factors. Here is a list of the top companies with the highest net buy volume on Monday and lowest price Friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. DELL INC (NASDAQ:DELL), JOHNSON & JOHNSON (NYSE:JNJ), ARENA PHARMACEUTICALS INC (NASDAQ:ARNA), YPF S.A.-SPONSORED ADR (NYSE:YPF), ENTEST BIOMEDICAL INC (OTC:ENTB), GENON ENERGY INC (NYSE:GEN). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  DELL    $0.120    0.98%     8,739,018    56.12%    6,829,616    43.86%    1,909,402    159,117 
  JNJ     $0.310    0.47%     9,630,097    38.94%    5,965,573    24.12%    3,664,524    118,210 
  ARNA    $0.960    11.43%    24,386,686   53.22%    21,307,255   46.50%    3,079,431    32,077  
  YPF     $0.180    1.61%     2,390,185    71.69%    304,439      9.13%     2,085,746    115,875 
  ENTB    $0.011    90.68%    10,810,946   55.03%    8,834,512    44.97%    1,976,434    1,847,135
  GEN     $0.070    5.47%     5,249,377    44.57%    2,881,509    24.46%    2,367,868    338,267 

For example, the chart above shows DELL with a Net Buy Volume of 1,909,402 shares and a Friction Factor of 159,117 shares. That means that it takes 159,117 more shares of buying than selling to move DELL higher by one penny. This means the Market Makers are allowing the stock to move up higher as of Monday (lower friction). And with one of the highest Net Buy Volumes, the combination of low friction and high net buy volume is bullish.

DELL INC (NASDAQ:DELL) - Dell Inc. provides integrated technology solutions in the information technology (IT) industry worldwide. The company designs, develops, manufactures, markets, sells, and supports mobility products, including laptops, netbooks, tablets, and smartphones; desktops PCs; and servers and networking products. It also offers storage solutions comprising storage area networks, network-attached storage, direct-attached storage, disk and tape backup systems, and removable disk backup. In addition, the company provides third-party software products consisting of operating systems, business and office applications, anti-virus and related security software, and entertainment software; and peripherals, such as printers, televisions, notebook accessories, mice, keyboards, networking and wireless products, and digital cameras. In addition, it offers IT and business services, including transactional services, such as support, managed deployment, enterprise installation, and configuration services; outsourcing services comprising data center and systems management, network management, life cycle application development and management, and business process outsourcing services; and project-based services consisting of IT infrastructure, applications, business process, and business consulting services, as well as offers asset recovery, recycling, and applications maintenance services. Further, the company provides financial services, including originating, collecting, and servicing customer receivables related to the purchase of its products. Dell Inc. sells its products and services through its sales representatives, telephone-based sales, and online at dell.com, as well as through indirect sales channels. The company was founded in 1984 and is headquartered in Round Rock, Texas.

JOHNSON & JOHNSON (NYSE:JNJ) - Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment provides products used in baby care, skin care, oral care, wound care, and womens health care fields, as well as nutritional, over-the-counter pharmaceutical products, and wellness and prevention platforms under the names JOHNSONS, AVEENO, CLEAN & CLEAR, JOHNSONS Adult, NEUTROGENA, RoC, LUBRIDERM, Dabao, Vendome, LISTERINE, REACH, BAND-AID, PURELL, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC. The Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, immunology, neurology, oncology, urology, and virology. Its products include REMICADE, a biologic approved for the treatment of immune mediated inflammatory diseases; PROCRIT, a biotechnology-derived product that stimulates red blood cell production; LEVAQUIN, which is used in the anti-infective field; RISPERDAL CONSTA, a injectable for the treatment of schizophrenia; CONCERTA, a product for the treatment of attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor; DURAGESIC/Fentanyl Transdermal, a treatment for chronic pain; VELCADE for the treatment of multiple myeloma; PREZISTA for treating HIV/AIDS patients; and INVEGA, a atypical antipsychotic. The Medical Devices and Diagnostics segment primarily offers circulatory disease management products; orthopaedic joint reconstruction, spinal care, and sports medicine products; surgical care, aesthetics, and womens health products; blood glucose monitoring and insulin delivery products; professional diagnostic products; and disposable contact lenses. The company was founded in 1886 and is based in New Brunswick, New Jersey.

ARENA PHARMACEUTICALS INC (NASDAQ:ARNA) - Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company also discovers small molecule drug candidates that target G protein-coupled receptors (GPCRs). Its clinical development programs include lorcaserin that has completed Phase III clinical trials for the treatment of weight management; APD791, an anti-thrombotic drug candidate, which completed Phase Ia and Phase Ib clinical trials; APD597 that is in Phase I clinical trials for the treatment of type II diabetes; APD916, which has completed preclinical development for the treatment of narcolepsy and cataplexy; and APD811, a preclinical drug candidate for the treatment of pulmonary arterial hypertension. The companys drug candidates use GPCR-focused drug discovery and development approach, as well as technologies, including Constitutively Activated Receptor Technology and Melanophore Technology. It has collaboration agreements with Ortho-McNeil-Janssen Pharmaceuticals, Inc. to further develop compounds for the potential treatment of type II diabetes and other disorders; and Merck & Co., Inc. to develop therapeutics for atherosclerosis and other disorders. Arena Pharmaceuticals also has a strategic cooperation agreement with Siegfried Ltd to manufacture lorcaserin. The company was founded in 1997 and is based in San Diego, California.

YPF S.A.-SPONSORED ADR (NYSE:YPF) - YPF SOCIEDAD ANONIMA, an energy company, engages in the exploration, development, and production of crude oil, natural gas, and liquefied petroleum gas (LPG) in Argentina. The company also involves in refining, marketing, transportation, and distribution of oil and a range of petroleum products, petroleum derivatives, petrochemicals, LPG, and bio-fuels; and gas separation and natural gas distribution operations. As of December 31, 2009, it operated approximately 70 oil and gas fields in Argentina; had proved reserves of approximately 538 million barrels of oil and 2,672 billion cubic feet of gas; and retail distribution network of 1,632 YPF-branded service stations for automotive petroleum products. The companys crude oil transportation network includes approximately 2,700 kilometers of crude oil pipelines with approximately 640,000 barrels of aggregate daily transportation capacity of refined products; crude oil tankage of approximately 7 million barrels; and terminal facilities at 5 Argentine ports. In addition, it participates in 3 power stations with an aggregate installed capacity of 1,622 megawatts. The company was founded in 1977 and is based in Buenos Aires, Argentina. YPF SOCIEDAD ANONIMA is a subsidiary of Repsol YPF, S.A.

ENTEST BIOMEDICAL INC (OTC:ENTB) - Entest BioMedical, Inc. engages in the development of stem cell therapy treatments for chronic obstructive pulmonary disease. The company also develops immuno-cancer therapies, testing procedures for diabetes, and stem cell research applications for diabetes and other illnesses. In addition, it involves in the medical device development, including stem cell extraction instrumentation. The company was founded in 2008 and is based in La Mesa, California. Entest BioMedical, Inc. is a subsidiary of Bio-Matrix Scientific Group, Inc.

GENON ENERGY INC (NYSE:GEN) - GenOn Energy, Inc. operates as a generator of wholesale electricity in the United States. Its portfolio of power generation facilities include baseload, intermediate, and peaking units using coal, natural gas, and oil to generate electricity. The company owns, contracts, or operates approximately 49 power generation stations with generation capacity of 24,599 megawatts. The company was formerly known as Mirant Corporation and changed its name to GenOn Energy, Inc. on December 4, 2010. The company is based in Houston, Texas.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net